Cereno Scientific announces first subjects dosed in clinical study with drug candidate CS1

Report this content

Cereno Scientific (Aktietorget: “CRNO B”), a pharmaceutical company developing a new preventive medicine to treat thrombosis-related disease, today announced dose administration for the first subjects in its recently approved clinical study with drug candidate, CS1.

The study, which is being conducted together with Cereno Scientific’s clinical research partner, CTC, is assessing the safety and tolerability, as well as the pharmacokinetics, of CS1 in adults with borderline hypertension and obesity. It is also investigating the efficacy of CS1 on biomarkers related to risk for thrombosis-related complications,

Thrombosis is the biggest cause of death in the world. Cereno Scientific aims to bring to market a new preventive medicine to treat thrombosis-related disease, offering an opportunity for more effective treatment while lowering the risk of major bleeding complications associated with current treatment with blood-thinning drugs.

The therapeutic potential of CS1 as a new treatment for the prevention of thrombosis has been demonstrated in preclinical studies. These studies have shown that it is possible to reduce thrombosis formation by stimulating the body’s own defence system against thrombosis, with no increased bleeding.

Cereno Scientific's CEO, Sten R Sorensen, comments:

“We are very pleased to have started this clinical study with CS1, a new potential medicine to prevent thrombosis-related disease.”  

Related press releases:

For more information about Cereno Scientific, please contact:
Sten R Sörensen, CEO
Tel. +46 733 74 03 74
E-mail: sten.sorensen@cerenoscientific.com

This information is information that Cereno Scientific AB is obliged to make public pursuant to the EU Market Abuse Regulation. The information was submitted for publication through the agency of the contact person set out above, on October 24, 2017. 

About Cereno Scientific AB
Cereno Scientific develops preventive medicines to treat thrombosis-related disease, such as myocardial infarction and stroke. These novel therapeutics stimulate the body's own intelligent clot-busting system, and are being developed to treat thrombosis-related cardiovascular diseases on the global market. Cardiovascular disease is currently the leading cause of death worldwide. Current therapies are connected to an increased risk of bleeding and, as a result, low effectiveness due to lower dosing levels. In turn leads to a high risk of new blood clots. The benefit with Cereno Scientific's drug candidate, CS1, is an improved balance between preventing blood clots and treatment-related side effects - leading to more effective treatment. CS1 is a re-formulation of a known compound and, as such, is expected to have a relatively short development time. It is based on many years of research and its effectiveness on risk factors is documented in experimental studies and early clinical studies. Preventive effectiveness against blood clots has been demonstrated in animal in vivo studies. Indication of clinical preventive effectiveness against heart attacks has been demonstrated in two large epidemiological studies. CS1 has a unique mechanism of action, a potentially wide range of indication opportunities connected to large blood clot-related diseases and, consequently, a large market potential. The Göteborg-based company is listed on the AktieTorget stock market, conducts research activities at AstraZeneca's BioVentureHub in Göteborg and is supported by GU Ventures. For more information, see www.cerenoscientific.se.






We are very pleased to have started this clinical study with CS1, a new potential medicine to prevent thrombosis-related disease.
Cereno Scientific's CEO, Sten R Sorensen